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SUMMARY 100 
Background & aims: The benefits of weight loss in subjects with metabolically healthy obesity 101 
(MHO) are still a matter of controversy. We aimed to identify metabolic fingerprints and their 102 
associated pathways that discriminate women with MHO with high or low weight loss response after 103 
a lifestyle intervention, based on a hypocaloric Mediterranean diet (MedDiet) and physical activity. 104 
Methods: A UPLC-Q-Exactive-MS/MS metabolomics workflow was applied to plasma samples from 105 
27 women with MHO before and after 12 months of a hypocaloric weight loss intervention with a 106 
MedDiet and increased physical activity. The subjects were stratified into two age-matched groups 107 
according to weight loss: <10% (low weight loss group, LWL) and >10% (high weight loss group, 108 
HWL). Random forest analysis was performed to identify metabolites discriminating between the 109 
LWL and the HWL as well as within-status effects. Modulated pathways and associations between 110 
metabolites and anthropometric and biochemical variables were also investigated. 111 
Results: Thirteen metabolites discriminated between the LWL and the HWL, including 1,5- 112 
anhydroglucitol, carotenediol, 3-(4-hydroxyphenyl)lactic acid, N-acetylaspartate and several lipid 113 
species (steroids, a plasmalogen, sphingomyelins, a bile acid and long-chain acylcarnitines). 1,5- 114 
anhydroglucitol, 3-(4-hydroxyphenyl)lactic acid and sphingomyelins were positively associated with 115 
weight variables whereas N-acetylaspartate and the plasmalogen correlated negatively with them. 116 
Changes in very long-chain acylcarnitines and hydroxyphenyllactic levels were observed in the HWL 117 
and positively correlated with fasting glucose, and changes in levels of the plasmalogen negatively 118 
correlated with insulin resistance. Additionally, the cholesterol profile was positively associated with 119 
changes in acid hydroxyphenyllactic, sphingolipids and 1,5-AG. 120 
Conclusions: Higher weight loss after a hypocaloric MedDiet and increased physical activity for 12 121 
months is associated with changes in the plasma metabolome in women with MHO. These findings 122 
are associated with changes in biochemical variables and may suggest an improvement of the 123 
cardiometabolic risk profile in those patients that lose greater weight. Further studies are needed to 124 
investigate whether the response of those subjects with MHO to this intervention differs from those 125 
with unhealthy obesity.  126 
1. Introduction 127 
Obesity comprises a variety of different metabolic profiles that diversify the risk of developing 128 
metabolic alterations that lead to diseases such as type 2 diabetes [1]. However, while obesity is 129 
usually associated with high cardiometabolic risk, it has been suggested that metabolically healthy 130 
obesity (MHO) has a different risk profile [2]. Subjects with MHO, despite having an excess of 131 
adipose tissue, present a propitious metabolic profile distinguished by higher insulin sensitivity, 132 
normal blood pressure, lower inflammatory parameters, lower visceral fat and more normal 133 
circulating lipid profiles than those with metabolically “unhealthy” obesity [1]. This may protect them 134 
from developing metabolic complications normally associated with obesity [3]. 135 
Men and womenwith obesity are advised or put on treatment to lose weight for better metabolic health 136 
[4]. However, it is as yet unclear whether subjects with an MHO phenotype will benefit from weight 137 
loss since they show a better cardiometabolic risk profile [1]. On the other hand, some studies have 138 
argued that the MHO condition may be a transient state towards a higher metabolic risk state. 139 
Therefore, it is important to investigate the effect of weight loss on cardiometabolic health 140 
intermediates in the MHO phenotype. Randomized controlled trials based on a Mediterranean diet 141 
(MedDiet) [5] and physical activity [6] have shown their beneficial effects on metabolic health per 142 
se. Moreover, when the two are combined even greater benefits have been demonstrated [7,8]. 143 
However, the impact of a lifestyle weight loss treatment on the MHO phenotype is poorly understood. 144 
Metabolomics is a powerful technique to define metabolic profiles through the comprehensive 145 
measurement of small molecule metabolites in a biological sample. The metabolome reflects the 146 
interaction of the exposome (i.e. the diet, gut microbiota and environmental agents to which an 147 
individual is exposed) with the gene cascade. Metabolomics can be used to identify biomarkers of 148 
prediction, progression or pathogenesis of conditions and diseases, as well as providing new clues 149 
regarding the mechanisms involved in metabolic deregulation [9,10]. Metabolomics may thus have 150 
advantages over other omics techniques in the study of diseases with a major metabolic component. 151 
In the present study, we aimed to investigate how the plasma metabolite profiles would be affected 152 
according to weight loss response to a long-term lifestyle intervention based on a hypocaloric 153 
MedDiet and increased physical activity in women with metabolically healthy obesity. This could 154 
provide insights into affected metabolic pathways and potential consequences for cardiometabolic 155 
health. 156 
2. Material and methods 157 
2.1. Subjects and study design 158 
Metabolically healthy women with obesity (BMI  30 kg/m2) aged 35e55 years were recruited by their 159 
family doctors between June 2013 and April 2014 from four primary health-care centers in the 160 
Malaga district of the Andalusian Health Service (Spain) [11]. A participant was considered to be 161 
metabolically healthy if they fulfilled 1 of the following criteria: elevated fasting plasma glucose (100 162 
mg/dL); elevated blood pressure (135/85 mmHg or use of blood pressure-lowering agents); elevated 163 
triglycerides (150 mg/ dL or treatment with lipid-lowering medication); or decreased HDL 164 
cholesterol (<50 mg/dL). Exclusion criteria were: presence of diabetes or impaired glucose tolerance 165 
as detected on a 2-h, 75-g oral glucose tolerance test (OGTT); pregnancy or planning to become 166 
pregnant during the study; cardiovascular disease; presence of any severe systemic disease such as 167 
advanced organ failure, cancer or dementia; immobilized individuals; alcohol or drug abuse; having 168 
participated in a weight loss programme in the past three months; or having lost 5 kg of body weight 169 
in the last six months. Participants were enrolled into a lifestyle weight-loss intervention with a 170 
hypocaloric MedDiet and a recommendation of physical activity for 12 months. The hypocaloric 171 
dietwas based on a reduction of about 600 kcal in the energy intake with a calorie distribution as 172 
follows: 35e40% fats (8e10% saturated fatty acids), 40e45% carbohydrates and 20% protein. 173 
Additionally, participants were recommended to practice daily exercise, which involved walking on 174 
average for 150 min every week throughout the study. 175 
The Rapid Assessment of Physical Activity questionnaire was used to determine the activity of the 176 
participants [12]. The dietary and physical intervention involved individual appointments with a 177 
nutritionist every week during the first two months, followed by monthly visits during the next four 178 
months and then once every three months up to 12 months. The study was conducted in accordance 179 
with the Declaration of Helsinki, all protocols were approved by the institutional ethical committee 180 
(Comite Coordinador de Etica de la Investigacion Biomedica de Andalucía) and all participants 181 
provided written informed consent. The clinical trial was registered at the ISRCTN registry 182 
(https://www.isrctn. com/ISRCTN88315555). Clinical measurements were taken at baseline and after 183 
12 months of intervention by trained health-careworkers, and included anthropometry (weight, 184 
height, waist and hip circumference, and bodycomposition), blood pressure and the collection of 185 
fasting blood samples. Biochemical analyses were performed in the laboratory of the reference 186 
hospital and conducted using routine methods. Energy and nutrient intakes were determined using a 187 
previously validated semi-quantitative 137-item food frequency questionnaire [13] and Spanish food 188 
composition tables [14,15]. Adherence to the MedDiet was measured using the 14-item screener from 189 
the PREDIMED study [16]. For the present study, participants were classified in two groups 190 
according to the percentage of weight loss after 12 months of intervention: <10% (low weight loss 191 
group, LWL) and >10% (high weight loss group, HWL).  192 
2.2. Metabolomics analysis 193 
All samples were kept at -80 ºC until analysis using the Metabolon analytical system (Metabolon 194 
Inc., Durham, North Carolina, USA) [17]. Briefly, proteins were precipitated with methanol under 195 
vigorous shaking for 2 min (Glen Mills Geno/Grinder 2000). One aliquot of the resulting supernatant 196 
was analyzed using an approach based on hydrophilic interaction liquid chromatography -ultra-197 
performance liquid chromatography (UPLC, Waters ACQUITY) coupled to a Thermo Scientific Q-198 
Exactive tandem mass spectrometer (MS/MS) using negative ion mode electrospray ionization (ESI-199 
). Three aliquots were analyzed by reverse phase (RP)- UPLC-ESI-MS/MS, two of them using 200 
positive ion mode electrospray ionization and the other using ESI-. The UPLC system was equipped 201 
with a UPLC C18 BEH (2.1  100 mm,1.7 mm) or UPLC BEH Amide (2.1  150 mm, 1.7 mm) column 202 
(Waters). The Q-Exactive system was interfaced with a heated ESI source and an Orbitrap mass 203 
analyzer operating at a 35,000 mass resolution and covering 70e1000 m/z was used. The MS analysis 204 
alternated between MS and data-dependent MSn scans using dynamic exclusion. Instrument 205 
variability was determined by calculating the relative standard deviation (RSD) for the internal 206 
standards that were added to each sample prior to injection into the MS. In parallel, overall process 207 
variability was determined by calculating the RSD for all endogenous metabolites present in all of 208 
the quality control samples created from a large pool of human plasma that were analyzed at the 209 
beginning and at the end of the experimental run and evenly throughout the run. The median RSD of 210 
the analytical platform instrumentation was 3%, whereas the median RSD overall process variability 211 
was 6%. These values reflected acceptable levels of variability for both instrument and overall 212 
process variability. Peaks were quantified using the area under the curve and metabolites were 213 
identified by comparing them to library entries of purified standards, according to retention time, 214 
accurate mass and MS/MS spectral data [18]. 215 
2.3. Statistical analysis 216 
All the statistical analyses and graphics were computed in R (version 3.3.3), unless otherwise 217 
specified. General characteristics of study participants, as well as anthropometric, clinical and dietary 218 
data, were examined through univariate statistical analyses. Fisher's exact test was used to compare 219 
categorical variables. For quantitative variables, data were analyzed using a non-parametric 220 
permutation test (n = 1000) of a mixed (within and between groups) factorial design using the ez 221 
package [19] to assess, respectively: i) between-group differences at baseline; ii) withingroup 222 
differences between before and after the intervention; and iii) between-group differences in the 223 
changes during the intervention. Quantitative data are expressed as median (interquartile range), 224 
whereas qualitative data are expressed as number of individuals (percentage). For metabolomics data, 225 
a multi-step process was carried out. Firstly, metabolites not found in at least 80% of the samples in 226 
either of the classes were removed (considering the time point and the weight loss group for the 227 
definition of classes). Missing values were imputed with the k-nearest neighbors method (k = 5) [20]. 228 
Data were scaled to set the median equal to 1 and log-transformed. Finally, the differences in 229 
metabolites between baseline and 12 months after the intervention periodwere calculated. Random 230 
forest analysis with repeated double cross-validation (RF-rdCV) was used to select metabolites that 231 
discriminated between the LWL and the HWL during the intervention process, as well as those 232 
metabolites that discriminated between baseline and the 12-month intervention within each group 233 
[19,21]. Briefly, RF-rdCV was performed using a procedure developed in-house [22]: the double 234 
cross-validation separated the cross-validation into an outer “testing” loop (n = 8 CV segments) and 235 
inner “tuning” (or validation) loop (n = 7 CV segments) to reduce bias from overfitting models 236 
[19,21]. The rdCV was repeated 30 times for between-group analysis and 20 times for within-group 237 
analysis and misclassification was used for the fitness of the model tuning. Metabolite selectionwas 238 
performed within the inner loop by iteratively turning over successively fewer features, keeping in 239 
the subsequent inner loop iterations the 80% most informative metabolites. The validity of the models 240 
was assessed using two-tailed permutation tests (n = 1000). Additionally, the p values of within- and 241 
between-group differences in the changes in metabolites selected by each RF-rdCV model were also 242 
calculated through intra- and inter-group permutation tests (n = 1000) using the above-mentioned ez 243 
package [19]. Finally, Spearman correlation coefficients were calculated to estimate the associations 244 
among the selected metabolites and with clinical variables. Metabolite-clinical correlations were 245 
represented as a heat map and metabolite-metabolite-clinical correlations as a network. These p 246 
values were adjusted by false discovery rate (FDR) multiple testing, based on the Benjamini-247 
Hochberg procedure, with the significant threshold set at p < 0.1 for the adjusted p values [23]. The 248 
Hmisc and ggplot packages were used for the analysis of correlation and the creation of the heat map, 249 
respectively. The correlation network was performed using Cytoscape 3.3.0. 250 
3. Results 251 
A total of 115 women with MHO were enrolled in the study. Of these, 43 dropped out during the 252 
intervention, six were excluded due to the presence of an illness, two for personal reasons and six for 253 
not having completed the food frequency questionnaires at both baseline and 12 months. Finally, 27 254 
women were randomly selected for metabolomics analysis based on previous experience from 255 
nutritional metabolomics experiments in order to achieve a resource-efficient proof-of-concept study. 256 
From the 27 women, 15 (55.6%) and 12 (44.4%) lost <10% and >10% of their body weight, 257 
respectively (Fig. S1). Table 1 presents the characteristics of these participants. In brief, the 258 
participants of both groups were of similar ages, and therewere similar proportions of menopause 259 
state, a high education level and smokers among them. Table 2 shows changes in clinical variables 260 
between the two groups. No baseline differences were observed in any of these variables between the 261 
groups. After 12 months, anthropometric and body composition parameters had improved in the 262 
HWL but remained unchanged in the LWL. The HWL also presented decreases in the OGTT and in 263 
glucose levels, but no changes in HbA1c, HOMA-IR or fasting insulin, whereas these three 264 
parameters increased in the LWL. Systolic blood pressure, as well as total, LDL and non-HDL 265 
cholesterol, also decreased in the HWL but did not do so in the LWL. These differences were also 266 
significant between the groups for most of the mentioned variables. At the beginning of the study the 267 
reported energy intake of the HWL was higher than that of the LWL (Table 3). Both groups showed 268 
decreases in energy intake through the study, but the women in the HWL presented significantly 269 
larger reductions, together with decreases in fat consumption, especially saturated and 270 
monounsaturated, and increases in protein intake. In general, the subjects in the HWL had a higher 271 
level of adherence to the treatment and also more of them followed the recommendations for physical 272 
activity in the HWL than in the LWL during the programme (Table 3). 273 
3.1. Impact of weight loss on plasma metabolomic profile 274 
Accurate classification predictions were obtained both between and within groups using the random 275 
forest classification scheme (Figs. 1, S2 and S3). While in between-group analysis, 24 out of 27 276 
(88.9%) individuals were correctly classified, in within-HWL analysis, 11 out of 12 (91.7%) were 277 
correctly classified, and in within- LWL analysis, all subjects were correctly classified (p values of 278 
permutation test <0.05). 279 
Thirteen metabolites were identified as determinants of the classification between weight loss groups, 280 
i.e. differences in 1,5- anhydroglucitol (1,5-AG), 3-(4-hydroxyphenyl)lactate (HPLA), 281 
Nacetylaspartate (NAA), the exogenous compound carotenediol, and nine lipids: 1 bile acid, 1 282 
plasmalogen, 1 phospholipid, 2 sphingolipids, 2 steroids and 2 acylcarnitines (Fig. 2). Twenty and 33 283 
metabolites, respectively, were selected from within-HWLandwithin-LWL analyses.1,5-AGwas also 284 
selected from within-LWL analysis,with higher levels at the 12-month intervention than at baseline. 285 
Sevenmetabolites fromthe between-group analysis were also selected from the within-HWL analysis 286 
(Fig. 3 and Fig. S4). Among these metabolites were the plasmalogen 1-(1-enyl-palmitoyl)- 2-oleoyl-287 
sn-glycero-3-phosphocholine (P-16:0/18:1) (GPC (P- 16:0/18:1)) and the exogenous compound 288 
carotenediol, which increased during the within-HWL intervention, and significantly more so than in 289 
the LWL (Fig. S5). The levels of HPLA and some lipids (two steroids and two sphingolipids) 290 
decreased after the intervention in the HWL and more so in the HWL than in the LWL.  291 
3.2. Correlation and pathway analysis 292 
Metabolites that were identified as discriminating between weight loss groups were correlated with 293 
changes in clinical variables (Fig. 4A), and their intercorrelations were mapped in an organic 294 
metabolic network (Fig. 4B). Positive correlations were presented between changes in the levels of 295 
1,5-AG, HPLA, SMs and carnitine C26 and weight variables, whereas changes in the levels of NAA, 296 
carotenediol, GPC (P-16:0/18:1) and GPC (18:1/18:2) correlated negatively with them. Furthermore, 297 
GPC (P-16:0/18:1) and carotenediol also correlated inversely with glycemic variables. In addition, 298 
several metabolites, including 1,5-AG, both SMs and HPLA, correlated positively with lipid 299 
biochemistry. Correlations between the selected metabolites in the within-group analyses and clinical 300 
variables are presented in Fig. S6. Finally, and in order to identify the most important metabolic 301 
pathways involved in these changes, pathway analyses were performed taking into account the 302 
discriminant metabolites selected from between-group analysis (Fig. 2) and from within-HWL (Fig. 303 
S4) and within-LWL (Fig. S5) analyses. No specific pathways were statistically significant using the 304 
metabolites selected as discriminant in the between-group RF model (Fig. S7). Statistically 305 
significant pathways altered in the HWL and in the LWL are shown in Fig. S8. 306 
4. Discussion 307 
Although several studies report the metabolic benefits of weight loss in subjects with obesity [7,24], 308 
the benefits of a lifestyle intervention for subjects with MHO are not clear. The present study 309 
demonstrated differences in the modulation of the plasma metabolome, stratified by weight loss, after 310 
a lifestyle weight loss programme based on a hypocaloric MedDiet and physical activity in 311 
metabolically healthy women with obesity. This study shows greater differences in carotenediol 312 
levels in the HWL after the intervention and these levels were also observed to increase in this group 313 
of women. Carotenediols are vitamin A precursors found mainly in vegetables and fruit-rich diets 314 
such as the MedDiet. An increase in their levels could reflect a higher intake of such foods, which is 315 
also reflected in their greater adherence to the Mediterranean pattern [25]. 1,5-AG discriminated 316 
between the HWL and the LWL and was observed to increase in women with lower weight loss. 317 
Similar results were observed in a 6-month intervention based on the New Nordic Diet, which is rich 318 
in vegetables, whole grains, nuts and seafood products [26,27]. This metabolite has in fact been 319 
proposed as a biomarker of short-term glycemic control and for screening undetected type 2 diabetes 320 
in saliva [28]. In line with our results, Lipsky et al. (2016) also observed a higher association of 1,5-321 
AG with BMI and adiposity indicators [29]. Small differences in the HWL likely reflect improved 322 
glycemic control as a result of a more successful intervention as measured by weight loss. Lipid 323 
metabolism has been extensively studied in obesity [30e33]. This study showed that lipid metabolism 324 
was altered, particularly in steroids, glycerophosphatidylcholines and sphingolipid metabolism. The 325 
steroids pathway was regulated differently in the two groups. Although androgen steroid sulfates 326 
decreased in the LWL, a higher decline was observed in the HWL. Similar behavior was observed by 327 
Ernst et al. (2013) when weight was lost after bariatric surgery [34]. 16a-hydroxy DHEA 3-sulfate 328 
(16OH-DHEA-S) and androstenediol (3beta,17beta) disulfate (ADIOL-DS) seem to be the major 329 
players in these changes. DHEA and ADIOL are interconverting molecules through the action of 17-330 
hydroxysteroid dehydrogenase [35]. However, while several studies have attributed an antiobesity 331 
role to DHEA-S [36], others have observed an inverse association between DHEA-S and the leptin 332 
hormone and satiety [37]. In addition, DHEA-S could play a role in the regulation of energetic balance 333 
in a fasting state or caloric restriction [38]. Steroid sulfation and desulfation are fundamental 334 
pathways for endocrine balance, specifically for fat mass distribution and glucose metabolism [39] 335 
regulated by sulfotransferases and sulfatase enzymes, respectively. These results could reflect an 336 
effect of modulation of the endocrine metabolism, especially in women of the HWL. SM (d18:0/22:0) 337 
and SM (d18/0/20:0, d16:0/22:0) were chosen by the multivariate model to discriminate between the 338 
HWL and the LWL. In addition, the overall sphingolipid profile decreased in both groups. 339 
Sphingolipids are the most prevalent class of lipid found in circulating LDL and activate 340 
inflammatory pathways [40]. Higher levels of sphingolipids are associated with obesity and related 341 
co-morbidities [30]. We observed a general decrease in these lipid species, which is in line with 342 
results reported after a lifestyle intervention in adolescents [41]. These two were selected and 343 
correlated with LDL, nHDL and CHOL. Thus, a downregulation of the sphingolipid pathway could 344 
indicate a better LDL profile and consequently potentially a reduction in the risk of developing 345 
cardiometabolic diseases. The plasmalogen GPC (P-16/18:0) discriminated between the HWL and 346 
the LWL and correlated negatively with adiposity variables. Plasmalogens act as an endogenous 347 
antioxidant produced by peroxisome. The production of plasmalogens is explained as a compensatory 348 
mechanism to protect the organism against higher oxidative stress such as in the development of 349 
metabolic syndrome [42]. Thus, an increase in GPC (P-16/18:0) levels in the HWL may indicate 350 
major protection of this group in the face of obesity complications. Strikingly, our study also reflects 351 
changes in lipid metabolism through changes in very long-chain acylcarnitines. We pointed out lower 352 
changes in the HWL than in the LWL. However, little is known about the role of very long-chain 353 
acylcarnitines in obesity and associated co-morbidities. Zhang et al. (2014) found higher 354 
concentrations of the carnitine C24, but not C26, in newly diagnosed type 2 diabetes subjects, and 355 
even in those with pre-diabetes, than in subjects with normal glucose tolerance [43]. Interestingly, 356 
higher levels of the C26 carnitine were detected in patients with a peroxisomal biogenesis disorder 357 
and it has been proposed as a biomarker in neurodegenerative disorders [44]. However, the 358 
implications of our findings are still uncertain. We also observed that NAA, a marker of neuronal 359 
density [45] in the central nervous system, discriminated between the HWL and the LWL. This is in 360 
line with previous research, which showed that subjects with overweight and diabetes presented lower 361 
levels of NAA in the hippocampus [46] and that NAA in the cortex was positively correlated with 362 
physical fitness in elderly adults [47]. Finally, the significant decrease in the HWL of HPLA and 363 
PLA, lactobacillus breakdown products of phenylalanine and tyrosine, respectively [48], could reflect 364 
either a decreased protein intake or a possible modulation of gut microbiota from the intervention. 365 
Subjects with obesity present higher levels of phenylalanine, tyrosine and leucine, among other amino 366 
acids [49,50]. In addition, higher levels of microbial product of HPLA were found in children with 367 
obesity [46]. HPLA has been proposed as a potential biomarker of a higher percentage of lean mass 368 
in young and healthy adults, though with an unknown mechanism [51]. Furthermore, positive 369 
correlations between changes in HPLA and weight loss, dyslipidemia parameters and OGTT and 370 
fasting glucose may suggest a possible global metabolic improvement in those subjects that benefited 371 
more from of lifestyle intervention. A major limitation of this work, inherent to the study design, is 372 
that findings cannot be conclusively attributed to weight loss per se, a better adherence to a MedDiet 373 
and/or physical activity due to confounding. In addition, at the beginning of the study, the HWL had 374 
a greater energy intake than the LWL. In addition to this, the sample size was small and a validated 375 
cohort and prospective study is needed to corroborate our results. Moreover, our results are gender 376 
dependent and therefore we cannot extrapolate our findings to the general population. However, this 377 
limitation also contributed to a strength of this study: the fact that all participantsweremiddle-aged 378 
women from a singlemetabolic phenotype reduced other sources of variability. Moreover, our 379 
findings have been obtained using a robust multivariate modeling procedure to acquire the most 380 
relevant biomarkers of high weight loss. These results show the potential of metabolomics for 381 
metabolic profiling and the identification of potential biomarkers in the onset of diseases. Overall, 382 
our results reveal that weight loss after a lifestyle intervention is associated with the modulation of 383 
lipid metabolism, sulfation activation and microbiota metabolism likely associated with a metabolic 384 
protective effect. Therefore, this study reinforces the idea that a healthy lifestyle, increased physical 385 
activity and weight loss lead to an improved metabolic health status in women with obesity, 386 
irrespectively of their initial metabolic state. Further studies are needed to investigate whether the 387 
response of those subjects with MHO to this intervention differs from that of those with unhealthier 388 
obesity. 389 
Funding 390 
This work was supported by the Joint Programming Initiative “A Healthy Diet for a Healthy Life” 391 
(JPI HDHL) [grant number FOODBALL- PCIN-2014-133], the award of the Generalitat de 392 
Catalunya’s Agency AGAUR [grant number 2017SGR1546] and the Instituto de Salud Carlos III de 393 
Madrid, Spain, PI12/01373, CIBERFES and CIBEROBN co-financed by the Fondo Europeo de 394 
Desarrollo Regional-FEDER. Additionally, this work was partly supported by a grant from the 395 
Associacio Catalana de Diabetis [Ajut de Recerca en Diabetis 2016, modalitat basica]. M.P.R was 396 
supported the APIFINSA- UB fellowship (University of Barcelona), and M Rosa Bernal- Lopez was 397 
supported by the “Miguel Servet Type I” programme (CP15/00028) from the ISCIII-Madrid (Spain), 398 
co-financed by the Fondo Europeo de Desarrollo Regional-FEDER. CA-L gratefully acknowledges 399 
the financial support by ICREA under the ICREA Academia programme. 400 
Conflicts of interest 401 
The authors declare no competing interests. 402 
CRediT authorship contribution statement 403 
Magali Palau-Rodriguez: Data curation, Formal analysis, Investigation, Methodology, Project 404 
administration, Visualization, Writing - original draft, Writing - review & editing. Mar Garcia-Aloy: 405 
Data curation, Formal analysis, Investigation, Methodology, Project administration, Visualization, 406 
Writing - original draft, Writing - review & editing. Antonio Miñarro: Data curation, Supervision, 407 
Writing - review & editing. M. Rosa Bernal-Lopez: Conceptualization, Resources, Validation, 408 
Writing - review & editing. Carl Brunius: Data curation, Supervision, Writing - review & editing. 409 
Ricardo Gomez-Huelgas: Conceptualization, Resources, Validation, Writing - review & editing. 410 
Rikard Landberg: Data curation, Supervision, Writing - review & editing. Francisco J. Tinahones: 411 
Conceptualization, Resources, Validation, Writing - review & editing. Cristina Andres-Lacueva: 412 
Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Validation, 413 
Writing - review & editing. 414 
Appendix A. Supplementary data 415 
Supplementary data to this article can be found online at https://doi.org/10.1016/j.clnu.2019.01.018. 416 
References 417 
[1] Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie M-E, Messier V, et al. Characterizing the 418 
profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011;35:971e81. 419 
https://doi.org/10.1038/ ijo.2010.216. 420 
[2] Wildman RP, Muntner P, Reynolds K, Mcginn AP. The obese without cardiometabolic risk factor 421 
clustering and the normal weight with cardiometabolic risk factor clustering. Arch Intern Med 422 
2008;168:1617e24. https://doi.org/10.1001/archinte.168.15.1617. 423 
[3] Spatola L, Badalamenti S. Metabolic healthy overweight/obese individuals: not just a restricted 424 
group. Clin Nutr 2018;37:2301. https://doi.org/10.1016/ j.clnu.2018.08.027. 425 
[4] García-Unciti M, Izquierdo M, Idoate F, Gorostiaga E, Grijalba A, Ortega- Delgado F, et al. 426 
Weight-loss diet alone or combined with progressive resistance training induces changes in 427 
association between the cardiometabolic risk profile and abdominal fat depots. Ann Nutr Metab 428 
2012;61:296e304. https://doi.org/10.1159/000342467. 429 
[5] Estruch R, Ros E, Salas-Salvado J, Covas M-I, Corella D, Aros F, et al. Primary prevention of 430 
cardiovascular disease with a mediterranean diet. N Engl J Med 2013;368:1279e90. 431 
https://doi.org/10.1056/NEJMoa1200303.  432 
[6] Palmnas MSA, Kopciuk KA, Shaykhutdinov RA, Robson PJ, Mignault D, Rabasa- Lhoret R, et 433 
al. Serum metabolomics of activity energy expenditure and its relation to metabolic syndrome and 434 
obesity. Sci Rep 2018;8:3308. https:// doi.org/10.1038/s41598-018-21585-6. 435 
[7] Elliot CA, Hamlin MJ. Combined diet and physical activity is better than diet or physical activity 436 
alone at improving health outcomes for patients in New Zealand's primary care intervention. BMC 437 
Public Health 2018;18:230. https:// doi.org/10.1186/s12889-018-5152-z. 438 
[8] Almanza-Aguilera E, Brunius C, Bernal-Lopez MR, Garcia-Aloy M, Madrid- Gambin F, 439 
Tinahones FJ, et al. Impact in plasma metabolome as effect of lifestyle intervention for weight-loss 440 
reveals metabolic benefits in metabolically healthy obese women. J Proteome Res 2018;17:2600e10. 441 
https://doi.org/ 10.1021/acs.jproteome.8b00042. 442 
[9] Neveu V, Moussy A, Rouaix H, Wedekind R, Pon A, Knox C, et al. Exposome- Explorer: a 443 
manually-curated database on biomarkers of exposure to dietary and environmental factors. Nucleic 444 
Acids Res 2017;45:D979e84. https:// doi.org/10.1093/nar/gkw980. 445 
[10] Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab 446 
2017;25:43e56. https://doi.org/10.1016/j.cmet.2016.09.018. 447 
[11] Rodriguez-Garcia E, Ruiz-Nava J, Santamaria-Fernandez S, Fernandez- Garcia JC, Vargas-448 
Candela A, Yahyaoui R, et al. Characterization of lipid profile by nuclear magnetic resonance 449 
spectroscopy (1H NMR) of metabolically healthy obese women after weight loss with Mediterranean 450 
diet and physical exercise. Medicine (Baltimore) 2017;96:e7040. https://doi.org/10.1097/ 451 
MD.0000000000007040. 452 
[12] Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MB. The Rapid assessment 453 
of physical activity (RAPA) among older adults. Prev Chronic Dis 2006;3:A118. 454 
[13] Fernandez-Ballart JD, Pi~nol JL, Zazpe I, Corella D, Carrasco P, Toledo E, et al. Relative 455 
validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population 456 
of Spain. Br J Nutr 2010;103:1808e16. 457 
https://doi.org/10.1017/S0007114509993837. 458 
[14] Mataix Verdú FJ. Tabla de composicio ́ n de alimentos. Instituto de Nutricion y Tecnología de 459 
Alimentos, Universidad de Granada; 2003. 460 
[15] Cervera P, Farran A, Zamora-Ros R. Tablas de composicio ́ n de alimentos CESNID = Taules 461 
de composicio ́ d’aliments del CESNID. Universitat de Barcelona; 2004. 462 
[16] Schroder H, Fito M, Estruch R, Martínez-Gonzalez MA, Corella D, Salas- Salvado J, et al. A 463 
short screener is valid for assessing mediterranean diet adherence among older Spanish men and 464 
women 1e3. J Nutr 2011;141: 1140e5. https://doi.org/10.3945/jn.110.135566. 465 
[17] Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh 466 
performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for 467 
the identification and relative quantification of the small-molecule complement of biological systems. 468 
Anal Chem 2009;81:6656e67. https://doi.org/10.1021/ac901536h. 469 
[18] Dehaven CD, Evans AM, Dai H, Lawton KA. Organization of GC/MS and LC/MS 470 
metabolomics data into chemical libraries. J Cheminform 2010;2:9. https:// doi.org/10.1186/1758-471 
2946-2-9. 472 
[19] Filzmoser P, Liebmann B, Varmuza K. Repeated double cross validation. J Chemom 473 
2009;23:160e71. https://doi.org/10.1002/cem.1225. 474 
[20] Gromski PS, Xu Y, Kotze HL, Correa E, Ellis DI, Armitage EG, et al. Influence of missing 475 
values substitutes on multivariate analysis of metabolomics data. Metabolites 2014;4:433e52. 476 
https://doi.org/10.3390/metabo4020433. [21] Breiman L. Random forests. Mach Learn 477 
2001;45:5e32. https://doi.org/ 10.1023/A:1010933404324.  478 
     479 
FIGURES 480 
 481 
Fig. 1. Results from repeated double cross-validated random forest analysis (rdCV-RF) to classify 482 
between weight loss groups: (A) Predictive classification of subjects according to weight loss group 483 
(misclassified individuals are highlighted with a circle); (B) Histograms for permutation tests (n = 484 
1000) of the rdCV-FR classification of subjects according to weight loss group. 485 
 486 
Fig. 2. Differences between weight loss groups in metabolites selected by repeated double-cross 487 
validated random forest model. p values were obtained by permutation test (n = 1000) of the 488 
differences of the changes between groups. 1,5-AG, 1,5-anhydroglucitol; 16OH-DHEA-S, 16a-489 
hydroxydehydroepiandrosterone 3-sulfate; ADIOL-DS (1), androstenediol (3b,17b) disulfate; 490 
carnitine C24, lignoceroylcarnitine; carnitine C26, cerotoylcarnitine; GCA-S, glycocholenate 491 
sulfate; GPC, glycerophosphocholine; HPLA, 3-(4- hydroxyphenyl)lactate; NAA, N-492 
acetylaspartate; SM, sphingomyelin. 493 
 494 
Fig. 3. Venn Diagram of metabolites discriminating between LWL and HWL, within-HWL and 495 
within-LWL, selected by repeated double-cross validated random forest modeling. 496 
 497 
Fig. 4. Correlations of changes between metabolites and clinical parameters during the intervention 498 
program: (A) Metabolite-clinical correlations; (B) Metabolite-metaboliteclinical significant 499 
correlations. Associations determined by Spearman correlations adjusting p values by FDR, with 500 
significant threshold set at p < 0.1. Negative correlations are colored in red and positive correlations 501 
are colored in blue. 1,5-AG,1,5-anhydroglucitol; 16-OH-DHEA-S, 16a-hydroxy DHEA 3-sulfate; 502 
ADIOL- DS, androstenediol (3beta,17beta) disulfate (1); BMI, body mass index; carnitine C26, 503 
cerotoylcarnitine (C26); carnitine C24, lignoceroylcarnitine (C24); CHOL, total cholesterol; DBP, 504 
diastolic blood pressure; FM, fat mass; GCA-S, glycocholenate sulfate; GPC (18:1/18:2), 1-oleoyl-505 
2-linoleoyl-GPC (18:1/18:2); GPC (P-16:0/18:1), 1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1); 506 
HbA1c, glycated hemoglobin A1c; HDL, high-density lipoproteins cholesterol; Hip, hip 507 
circumference; HOMA-IR, insulin resistance calculated by homeostatic model assessment; HPLA, 508 
3-(4- hydroxyphenyl)lactate; LDL, low-density lipoproteins cholesterol; LM, lean mass; NAA, N-509 
acetylaspartate; OGTT, oral glucose tolerance test; non-HDL, non-high-density lipoproteins 510 
cholesterol; SBP, systolic blood pressure; SM sphingomyelin; TG, triglycerides; Waist, waist 511 
circumference. (For interpretation of the references to color in this figure legend, the reader is 512 









    
